Chesapeake Regional first to offer only FDA-approved drug coated balloon in Hampton Roads

bigstock-Clogged-Artery-61575236 webChesapeake Regional Medical Center recently began using the Lutonix® 035 Drug Coated Balloon PTA Catheter (DCB) for percutaneous transluminal angioplasty (PTA), a minimally invasive procedure used to open blocked arteries in patients with peripheral arterial disease (PAD). CRMC is the only hospital in Hampton Roads to use this device, performing the first successful case Nov. 4.

“The Lutonix® 035 Drug Coated Balloon helps deliver medicine directly to the artery, which significantly lowers the risk of the blockage returning, without closing the door to other treatment options down the road,” said Christopher L. Stout, M.D., a vascular surgeon who is on staff at Chesapeake Regional Medical Center and performed the first procedure in Hampton Roads. “This piece of technology is just one of the ways we are bringing innovative care to our patients at Chesapeake Regional.”

The device, the first and only DCB approved by the U.S. Food and Drug Administration (FDA), is used to treat patients with PAD. This is a life-threatening condition where the arteries narrow with the build-up of plaque often in the legs, arms, stomach and head. According to the American Heart Association, PAD affects approximately 8.5 million Americans each year. PAD is often asymptomatic until 60 percent of the artery is blocked, which can put the patient at high-risk for heart attack, stroke or amputation if left untreated. Treatment can include PTA or more invasive vascular bypass surgery, and most cases of PAD are managed easily once diagnosed.

Successful treatment of PAD requires improved blood flow for longer periods of time. A recent clinical study demonstrated superior primary blood flow with the Lutonix® 35 DCB for the efficacy endpoint.  

For more information about Chesapeake Regional’s cardiovascular program, visit or call 757-312-8121.


Chesapeake Regional prepared for Ebola

Chesapeake Regional Medical Center's Infection Prevention and Control Department, under the guidance of the Infection Control Committee, has revised the previously posted Ebola Management Plan to include the updated guidelines released by the Centers for Disease Control and Prevention (CDC) regarding personal protective equipment. As this is a rapidly changing situation, this document will be continuously updated to incorporate the latest guidelines and/or recommendations from CDC and the Virginia Department of Health. This plan can be accessed by clicking here.

If you have questions regarding Ebola transmission or this management plan, please feel free to contact the Infection Prevention and Control Department at 312-6172 or 312-3172.

Chesapeake Regional offers 3D mammography

Advanced new 3D technology available at Chesapeake Regional Medical Center coordinates with 2D mammography and breast MRI to increase the rate of breast cancer detection and reduce the amount of unnecessary return visits for repeat breast screenings.

According to a recent study by the Journal of the American Medical Association tomosynthesis-or 3D mammography-can also increase the detection of more invasive and deadly cancers. The study involved nearly half a million women, and determined that 3D mammography, combined with traditional 2D mammography, was associated with a 41 percent increase in the detection rate of invasive cancers and a 15 percent drop in additional screenings for false alarms.

"We are the only facility in the area to offer C-View(tm), which provides us with the technology to obtain both of the recommended 3D and 2D images during the same screening," said Michael Petruschak, M.D., a radiologist who practices with Chesapeake Radiologists, Ltd. and is the director of breast imaging for CRMC. "This reduces exposure to radiation and provides our patients with the latest in breast cancer technology."

Tomosynthesis was approved by the FDA in 2011, and was created in-part due to criticism of traditional mammography. Critics highlighted its tendency to identify false alarms and the inability to view potentially cancerous lesions through dense breast tissue.

"Conventional digital mammography has always been hampered by overlapping breast tissue," said Petruschak. "With 3D mammography this is no longer an issue, especially with dense breast tissue. The images represent individual slices through the breast. Each area is clearly identified and is not masked by neighboring tissue."

According to Petruschak, conventional mammography should not be discounted and will have a role in breast imaging for some time to come. Not only because the 2D images are still necessary for the interpretation of the 3D images, but also because any mammogram is better than avoiding screening totally.

"Whether 2D or 3D, one of the most important things women can do is get a yearly mammogram beginning at age 40," said Petruschak. "I have seen many women both personally and professionally delay mammograms. By avoiding breast screening until you have found a lump, you are greatly reducing your chances of a full recovery."

The American College of Radiology and American Cancer Society still recommend that women age 40 or older should have a yearly mammogram and should do so as long as they are in good health. Those with family or personal histories that put them at a higher risk for breast cancer may need to be screened earlier. Your primary care physician can help you to determine your risk category and when you should begin routine screening.

Women do not need a referral for 3D mammography at CRMC. Because the technology is still new, many insurance plans will not cover it. However, CRMC will offer 3D screening mammograms for a $50 charge. These screenings are currently available by request. Diagnostic 3D mammograms are also currently available and are billed as a diagnostic mammogram.

To schedule a 3D mammography at Chesapeake Regional Medical Center, call 312-6137.